U.Va. clinical trials precede FDA emergency use authorization of convalescent plasma as COVID-19 treatment
As coronavirus cases continued to rise and nationwide rates staggered, the U.S. Food and Drug Administration announced convalescent plasma as an emergency-use authorization treatment for COVID-19 on Aug. 23. At that time, the FDA concluded that convalescent plasma looked to be a promising, safe and effective treatment for patients who have contracted the virus. Since May 5 of this year, trials on this method of treatment have already been conducted at the University.